Glioblastoma’s Lethal Gap Erased: GPNMB CAR-Ts Rewrite Cancer Medicine

The clinical validation of GPNMB-targeted CAR-T cells has eliminated detectable glioblastoma tumors and neutralized tumor-associated macrophages in preclinical models, marking a decisive transition from cytotoxic therapy to systemic immune reprogramming. This breakthrough, published in Nature on July 1, 2026, directly targets the immunosuppressive microenvironment that previously rendered all brain cancer treatments ineffective. The implications extend far beyond neurology, offering a scalable platform for multi-organ cancers and fundamentally reshaping global healthcare economics and biotech competition.